BioCentury
ARTICLE | Clinical News

HSV-2 theracine: Began Phase I/II trial

May 1, 2000 7:00 AM UTC

AuRx Inc., Baltimore, Md. Product: HSV-2 theracine Business: Infectious diseases Therapeutic category: Immune stimulation, Viral replication Target: Immune cells Description: Live recombinant herpes v...